Key Stakeholders' Knowledge, Opinions, and Interests on Real‐World Evidence in the Regulatory Process—Results of an EU ‐Wide Survey
Authors:
- Frank Lucas DepnerFDFrank Lucas Depner
- Martin RussekMRMartin Russek
- Christoph RöthleinCRChristoph Röthlein
- Cornelia BeckerCBCornelia Becker
- Jonas PeltnerJPJonas Peltner
- Kerstin PfeiferKPKerstin Pfeifer
- Evy ReviersEREvy Reviers
- Dirk De ValckDVDirk De Valck
- Julia WicherskiJWJulia Wicherski
- Sirpa HartikainenSHSirpa Hartikainen
- Anna‐Maija TolppanenATAnna‐Maija Tolppanen
- Britta HaenischBHBritta Haenisch
Open Access
- 20 December 2025
- journal article
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (12) , e70454
Abstract
Real‐world data (RWD) and real‐world evidence (RWE) are increasingly gaining attention in supporting drug regulatory decision making. This study assessed knowledge, opinions, and usage patterns of key stakeholders regarding the status of RWD/RWE and AI implementation in health technology assessment (HTA) and drug regulation and aimed to identify the primary obstacles hindering adoption of these technologies. Four surveys tailored to different stakeholders were created and disseminated online to the respective target groups, including I) regulatory authorities, HTA bodies, and the pharmaceutical industry, II) academia, III) payers, and IV) patients and physicians. The responses were analyzed using descriptive statistics or qualitative content analysis with inductive coding. The survey was active from May 6, 2024 to June 30, 2024. Altogether, 221 respondents participated in the survey. Among respondents from regulatory/HTA authorities or industry, 75.4% viewed RWD/RWE as important for future decision making. Respondents from this group already using RWD ( n = 56) most frequently reported obstacles regarding data quality (89.3%), data access (62.5%), and data‐coding standardization (57.1%). Patients and physicians predominantly had positive expectations about the use of RWD/RWE, and 94.3% indicated willingness to share healthcare data for research, but all respondents also expressed concerns, with data privacy being most frequently mentioned (75.5%). The results show that although stakeholders are optimistic about RWD/RWE implementation into regulatory practice, our survey suggests that successful implementation may benefit from further development in several areas, including guideline harmonization, RWD infrastructure optimization and accessibility, and professional education.Keywords
This publication has 28 references indexed in Scilit:
- How Comorbidities Shape Cancer Biology and SurvivalTrends in Cancer, 2021
- Patients’ and public views and attitudes towards the sharing of health data for research: a narrative review of the empirical evidenceJournal of Medical Ethics, 2019
- Patient perspectives on the linkage of health data for research: Insights from an online patient community questionnaireInternational Journal of Medical Informatics, 2019
- Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for EuropeClinical Pharmacology & Therapeutics, 2019
- Randomized controlled trials – a matter of designNeuropsychiatric Disease and Treatment, 2016
- Innovation in the pharmaceutical industry: New estimates of R&D costsJournal of Health Economics, 2016
- Patient and Public Views on Electronic Health Records and Their Uses in the United Kingdom: Cross-Sectional SurveyJournal of Medical Internet Research, 2013
- Characterisation of COPD heterogeneity in the ECLIPSE cohortRespiratory Research, 2010
- Observational Studies Are Complementary to Randomized Controlled TrialsNephron Clinical Practice, 2009
- The Epidemiology of Major Depressive DisorderJAMA, 2003